These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37038063)

  • 1. Prostate cancer-what about oligometastatic disease and stereotactic ablative radiotherapy?-a narrative review.
    Mikropoulos C; Saxby H; Boussios S
    Ann Palliat Med; 2023 May; 12(3):646-652. PubMed ID: 37038063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
    Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
    Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
    Sritharan K; Rieu R; Tree A
    Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
    Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
    JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer.
    Abdel-Aty H; James ND
    Curr Opin Urol; 2022 May; 32(3):277-282. PubMed ID: 35249966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
    Doyle E; Killean AJ; Harrow S; Phillips ID
    Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer.
    Saxby H; Boussios S; Mikropoulos C
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
    Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
    JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
    Saluja R; Cheung P; Zukotynski K; Emmenegger U
    Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
    Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
    Front Oncol; 2022; 12():863609. PubMed ID: 35494057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
    Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
    BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
    Dohopolski M; Iyengar P
    Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
    Moyer CL; Phillips R; Deek MP; Radwan N; Ross AE; Antonarakis ES; Reyes D; Wright J; Terezakis SA; Song DY; DeVille C; Walsh PC; DeWeese TL; Carducci M; Schaeffer EM; Pienta KJ; Eisenberger M; Tran PT
    World J Urol; 2019 Dec; 37(12):2623-2629. PubMed ID: 30191396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.